Browse News
Filter News
Found 45 articles
-
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
2/8/2024
We have successfully dosed the first of three patients in Cohort 8, the last cohort of the Phase 1 dose-ranging part of the Phase 1/2 clinical trial in newly diagnosed uMGMT Glioblastoma Multiforme patients.
-
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
7/28/2023
Genenta Science announced that the Phase 1 dose-ranging clinical trial in Glioblastoma Multiforme (TEM1-GBM) is progressing in line with the development program.
-
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
6/29/2023
Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the European Commission has granted Orphan Drug Designation (ODD) to Temferon™ for the treatment of glioma.
-
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
4/26/2023
Genenta Science S.p.A. today announced its fiscal year 2022 financial results and that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 (the “Annual Report”) with the Securities and Exchange Commission ("SEC").
-
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme
3/2/2023
Genenta Science today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Temferon™ for the treatment of glioblastoma multiforme (GBM).
-
Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement
2/7/2023
Genenta Science has entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs.
-
Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer
1/17/2023
Corium Pharma Solutions, Inc. today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors.
-
Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients
11/7/2022
Genenta Science will present at the 2022 annual meeting of the Society for Immunotherapy of Cancer (SITC) data showing signs of Temferon-induced changes in the tumor microenvironment of patients affected by glioblastoma multiforme and activation of the immune system that may result in the inhibition of tumor growth.
-
Genenta Provides First Half 2022 Business Update and Financial Results
10/24/2022
Genenta Science provides business and financial results for the six months ended June 30, 2022.
-
Genenta to Present at Upcoming Scientific and Investor Conferences - October 05, 2022
10/5/2022
Genenta Science, a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming scientific and investor conferences.
-
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
5/13/2022
Genenta Science will be presenting at several upcoming scientific congresses in May and June.
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
Genenta Appoints Industry Veteran Tim Obara as Head of Business DevelopmentExtensive experience in business development with AstraZeneca and GSK
5/9/2022
Genenta Science announces the appointment of Tim Obara, a highly experienced commercial healthcare executive, as Vice President Business Development.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme
5/4/2022
Genenta Science announces that its ongoing trial of Temferon™ in glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM) has escalated to the next planned dose.
-
Genenta Files Annual Report on Form 20-F for Fiscal Year 2021
5/4/2022
Genenta Science S.p.A. announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the Securities and Exchange Commission on May 2, 2022.
-
Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in GlioblastomaInitial evidence of potential to modulate tumor microenvironment
5/2/2022
Genenta Science announces that preliminary findings from its Phase 1/2a of Temferon™ in the treatment of patients with glioblastoma multiforme patients who have an unmethylated MGMT gene promoter provide initial evidence of Temferon’s potential for modulating the tumor microenvironment as well as details of Temferon’s continuing positive safety profile and signals of biological activity.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Genenta Announces Nomination of Mark A. Sirgo as Chair
4/27/2022
Genenta Science announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair.